Active, currently enrolling
A Multicenter, Open-Label, Extension Study to Assess the Long-Term Safety and Efficacy of CTP-543 in Adult Patients With Moderate to Severe Alopecia Areata.
NCT No.: NCT03898479
Study Type: INTERVENTIONAL
Phase:
Phase II
Region: California - Northern
Acronym: CTP-543
Official Title
A Multicenter, Open-Label, Extension Study to Assess the Long-Term Safety and Efficacy of CTP-543 in Adult Patients With Moderate to Severe Alopecia Areata.
Purpose
The overall objectives of the study are to evaluate long-term safety of CTP-543 and to assess long-term effects of CTP-543 on treating hair loss in adult patients with chronic, moderate to severe alopecia areata.
Detailed Description
Eligibility Criteria
Inclusion Criteria
- Have completed 24 weeks of treatment in a previous qualifying CTP-543 clinical trial
|
Exclusion Criteria
- Active scalp inflammation, psoriasis, or seborrheic dermatitis requiring topical treatment to the scalp, significant trauma to the scalp, or untreated actinic keratosis
|
-
Females who are nursing, pregnant, or planning to become pregnant while in the study, and for 30 days after last dose of study medication
|
-
Donation of blood at any point throughout the study and for 30 days after last dose of study medication
|
Keywords and/or Specific Medical Conditions
|
|
|
|
|
|
|
|
|
|
-
Pathological Conditions, Anatomical
|
|
|
|
|
|
|
Sponsors
|